RxDoctor Payments Data

Mohan Rengen, DO

Gastroenterology · Camp Hill, PANPI 1801846043

Payments from drug & device makers

$2,283in general payments, 2019–2025

Across 111 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$381
  • AbbVie$341
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$333
  • Madrigal Pharmaceuticals$315
  • Ardelyx, Inc.$171
  • Takeda Pharmaceuticals U.S.A., Inc.$151
  • plus $591 from 15 others
$1,500in research payments, 2019–2025

Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K

What the payments were for

  • Food & beverage$2,276100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,283 in reported general payments places this provider in the 50th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$55,189
Medicare patients
295
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xeljanz XrTofacitinib Citrate12$129,452
LinzessLinaclotide39$30,503
XifaxanRifaximin12$27,334
Mesalamine24$22,674
Dexlansoprazole DrDexlansoprazole62$17,124
SutabSod Sulf/Pot Chloride/Mag Sulf31$4,874
Pantoprazole Sodium317$3,497
Dicyclomine Hcl49$2,212
Sucralfate37$1,902
Esomeprazole Magnesium56$1,899
Famotidine123$1,457
Omeprazole93$1,238
Ondansetron OdtOndansetron37$789
CholestyramineCholestyramine (With Sugar)19$683
Lansoprazole19$496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$341$30,50339 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$333$27,33412 claims
Braintree Laboratories, Inc.Sutab$66$4,87431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →